ROCM Rochester Medical Corp. (MM)

STEWARTVILLE, Minn., April 29 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (NASDAQ:ROCM) today announced operating results for its second quarter ending March 31, 2008. The Company reported record sales of $9,215,000 for the quarter compared to $8,347,000 for the second quarter of last year. Last year's revenues included a one time recording of a $525,000 deferred asset related to a marketing fee paid to Rochester Medical by Coloplast A/S. The Company reported a Net Loss of $167,000 or $.01 per diluted share compared to a Net Income of $1,044,000 or $.08 per diluted share for the second quarter of last year. Rochester Medical Branded Sales increased approximately 24% for the quarter. Excluding last year's realization of the $525,000 deferred asset, Private Label sales increased by 9% for the quarter resulting in an overall net sales increase of 18% for the quarter. Net Income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter was $531,000 or $.04 per diluted share compared to Non-GAAP Net Income of $1,041,000 or $.08 per diluted share for the second quarter of last year. The decrease for the quarter is primarily attributable to the Company's strategic decision to significantly increase its investment in Sales and Marketing personnel and programs. This increase has been carefully planned and implemented as a response to several key factors. First there is greatly heightened interest in infection control catheters as a result of scheduled Medicare reimbursement changes that will no longer pay hospitals for costs associated with treatment of Catheter Associated Infections. The change becomes effective October 1, 2008. Rochester Medical has the only Drug-Eluting Anti-Infection Foley Catheter in the marketplace. The increased investment in Sales and Marketing is also designed to allow the Company to better service the changing dynamics of the Intermittent Catheter marketplace resulting from recent Medicare reimbursement changes allowing for significantly increased sterile one-time catheter usage in order to prevent infections. In addition, the increased resources and programs are strongly focused on promotion and sale of products in the United Kingdom. Regarding the quarter, Anthony J. Conway, Rochester Medical's CEO and President said, "Our Investment for Growth Strategy is off to an excellent start. As a result of this increased investment for the future we now have a well fortified Sales, Marketing, and Customer Service Team in place. Going forward, I believe the Company is well positioned to leverage our advanced proprietary products for strong gains in our key markets." Rochester Medical has provided Non-GAAP Net Income in addition to earnings calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Non-GAAP Net Income is not a measure of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income is not comparable to information provided by other companies. Non-GAAP Net Income has limitations as an analytical tool and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of Net Income and Non-GAAP Net Income are presented at the end of this press release. The Company will hold a quarterly conference call this afternoon to discuss its earnings report. The call will begin at 4:00 p.m. Central Daylight Time (5:00 p.m. eastern time). This call is being webcast by Thomson/CCBN and can be accessed at Rochester Medical's website at http://www.rocm.com/. To listen live to the conference call via telephone, call: Domestic: 888.713.4213, password 19121219 International: 617.213.4865, password 19121219 Pre Registration: https://www.theconferencingservice.com/prereg/key.process?key=PNHDUFLFK Replay will be available for seven days at http://www.rocm.com/ or via telephone at: Domestic: 888-286-8010, password 73150129 International: 617-801-6888, password 73150129 The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.fulldisclosure.com/, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (http://www.streetevents.com/). This press release contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2007. Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company markets under its own Rochester Medical(R) brand and under existing private label arrangements. For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at http://www.rocm.com/. ROCHESTER MEDICAL CORPORATION Reconciliation of Reported GAAP Net Income to Non-GAAP Net Income For the Three and Six months ended March 31, 2008 (unaudited) (unaudited) Three months ended Six months ended March 31, March 31, 2008 2007 2008 2007 GAAP Net Income as Reported $(166,858) $1,043,518 $104,696 $32,510,134 Diluted EPS as Reported $(0.01) $0.08 $0.01 $2.64 Adjustments for non-recurring unusual items: Settlement income after taxes (1) - - - (31,305,000) Deferred revenue (2) - (525,000) - (564,286) Subtotal - (525,000) - (31,869,286) Adjustments for recurring non-cash expenses: Intangible Amortization (3) 163,000 163,000 326,000 326,000 FAS 123R Compensation Expense (4) 535,000 359,000 786,000 1,461,000 Subtotal 698,000 522,000 1,112,000 1,787,000 Non-GAAP Net Income $531,142 $1,040,518 $1,216,696 $2,427,848 Non-GAAP Diluted EPS $0.04 $0.08 $0.10 $0.20 Weighted Average Shares -- Diluted 11,822,435 12,475,859 12,557,214 12,331,312 (1) Settlement income received November 20, 2006 from Premier, Inc. of $5,155,000 and December 14, 2006 from CR Bard, Inc. of $33,450,000 after taxes of $7,300,000. This adjustment reduces net income for amounts received net of taxes paid in connection with one-time settlement of certain litigation. These amounts were recorded in Other Income in the Statement of Operations for the fiscal year ended September 30, 2007. (2) Deferred revenue from a $1,000,000 fee paid by Coloplast A/S in June 2002 for marketing rights to our antibacterial Release NF foley catheter. These rights with Coloplast A/S were cancelled by mutual agreement in March 2007, thus accelerating the recognition of the remaining amount as all conditions for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related to the realization of certain one-time revenue from marketing rights. The amounts were recorded in net sales in the Statement of Operations. (3) Amortization of the intangibles acquired in June 2006 asset acquisition from Coloplast AS and Mentor Corporation. Management believes these assets are appreciating. This adjustment adds back amortization expense for the three and sixth months ended March 31, 2007 and 2006 related to certain intangibles. (4) Compensation expense mandated by SFAS 123R. This adjustment adds back the compensation expense recorded when stock options are granted to employees and directors for the three and sixth months ended March 31, 2007 and 2006. Rochester Medical Corporation Press Release -- F08 Second Quarter Condensed Balance Sheets (unaudited) March 31, September 30, 2008 2007 Assets Current Assets Cash and equivalents $9,118,124 $6,671,356 Marketable securities 26,456,481 30,465,244 Accounts receivable 6,854,479 5,527,518 Inventories 7,809,858 7,698,889 Prepaid expenses and other assets 704,401 6,480 Deferred income tax asset 1,105,255 876,032 Total current assets 52,048,598 51,245,519 Property and equipment, net 9,706,058 9,679,035 Deferred income tax asset 787,753 571,721 Patents, net 238,342 257,353 Intangible assets, net 7,426,253 7,821,562 Goodwill 5,765,200 5,920,255 Total Assets $75,972,204 $75,495,445 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $1,913,309 $1,091,874 Accrued expenses 860,760 1,978,937 Short-term debt 1,859,770 1,849,463 Total current liabilities 4,633,839 4,920,274 Long-term liabilities Long-term debt 5,487,887 6,066,246 Total long term liabilities 5,487,887 6,066,246 Stockholders' equity 65,850,478 64,508,925 Total Liabilities and Stockholder Equity $75,972,204 $75,495,445 Rochester Medical Corporation Press Release -- F08 Second Quarter Summary Statements Of Operations (unaudited) (unaudited) Three months ended Six months ended March 31, March 31, 2008 2007 2008 2007 Sales $9,215,238 $8,346,603 $17,438,526 $15,858,569 Cost of sales 4,942,975 3,919,245 9,025,460 7,655,589 Gross profit 4,272,263 4,427,358 8,413,066 8,202,980 Gross profit % 46% 53% 48% 52% Costs and expense: Marketing and selling 2,380,306 1,520,685 4,604,671 2,754,347 Research and development 304,257 240,495 533,200 443,265 General and administrative 2,016,767 1,709,553 3,631,885 3,758,699 Total operating expenses 4,701,330 3,470,733 8,769,756 6,956,311 Income from operations (429,067) 956,625 (356,690) 1,246,669 Other income (expense) Interest income 355,646 439,503 808,986 514,353 Interest expense (128,834) (153,184) (278,323) (312,822) Other income - - - 38,605,000 Net income (loss) before income taxes $(202,255) $1,242,944 $173,973 $40,053,200 Income tax expense(benefit) (35,397) 199,426 69,277 7,543,066 Net income (loss) (166,858) 1,043,518 104,696 32,510,134 Earnings (loss) per common share -- Basic $(0.01) $0.09 $0.01 $2.89 Earnings (loss) per common share -- Diluted $(0.01) $0.08 $0.01 $2.64 Weighted Average Shares: Basic 11,822,435 11,367,295 11,776,083 11,233,207 Weighted Average Shares: Diluted 11,822,435 12,475,859 12,557,214 12,331,312 DATASOURCE: Rochester Medical Corporation CONTACT: Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation, +1-507-533-9600 Web site: http://www.rocm.com/ http://www.streetevents.com/ http://www.fulldisclosure.com/

Copyright